Barrington Research lowered shares of Rosetta Genomics (NASDAQ:ROSG) from an outperform rating to a market perform rating in a research report sent to investors on Monday, MarketBeat.com reports.

Rosetta Genomics (NASDAQ:ROSG) opened at $0.52 on Monday. Rosetta Genomics has a twelve month low of $0.48 and a twelve month high of $6.96. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 0.03.

COPYRIGHT VIOLATION WARNING: This news story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/21/rosetta-genomics-rosg-cut-to-market-perform-at-barrington-research.html.

About Rosetta Genomics

Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).

Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.